Oxford will license its SnapFast platform to Twist, to provide it with a range of application-specific expression vectors it can use to clone synthesized DNA.
Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.
The yet-to-be-named entity will draw on the partners' respective resources in synthetic biology and plant and agricultural products.
The Series A round included investments from Illumina Ventures, Merck KGaA's M Ventures, Sofinnova Partners, Kurma Partners, and Idinvest Partners.
The two companies will work in tandem to provide customers worldwide with access to genes up to 70 kilobases in length.
The collection will be made available by BioBricks at no cost to the research community.
Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology.
Through the deal, Ginkgo has picked up Gen9's manufacturing platform and suite of proprietary technologies, software, and informatics tools for DNA synthesis and assembly.
The company intends to use the proceeds of the round to advance its proprietary enzymatic DNA synthesis technology called EcoDNA.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.